Lutathera is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How do you pay?

How to pay the least

Given by your care team

Billed by the clinic

Lutathera is given by a doctor or nurse, not picked up at a pharmacy.

  1. Ask your care team or your plan what you’d pay before your visit.

Compare every option

Question
Brand nameLutathera
Authorized genericlutetium lu 177 dotatate
Regular genericlutetium lu 177 dotatate
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Lutathera?
The original
–
–

Brand nameThe maker’s card

Novartis Patient Support Co-Pay Program

Savings card from Novartis

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a treatment

The card takes up to $15,000 per course of treatment off your co-pay.

Sign up on us.lutathera.com 

Or call 1-844-638-7222.

In the maker’s words

“If you have private insurance, you could be eligible for co-pay support and may pay as little as $0 for your LUTATHERA treatment.”

From the maker’s offer on us.lutathera.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Lutathera itself, from the same company, sold without the brand name, and usually for less. For now Lutathera is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

LUTATHERA is a radiolabeled somatostatin analog indicated for the treatment of adult and pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors.

Source: the FDA label for Lutathera (Advanced Accelerator Applications USA, Inc), January 15, 2026. Full label on DailyMed 

Good to know